查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2095005

肝癌診斷市場－2026-2032年全球市場預測

Liver Cancer Diagnostics Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，肝癌診斷市場將成長至 169.7 億美元，複合年成長率為 6.81%。

主要市場統計數據
基準年 2025 107億美元
預計年份：2026年 113.8億美元
預測年份 2032 169.7億美元
複合年成長率 (%) 6.81%

肝癌的診斷正從零星發現轉向基於風險的綜合性疾病監測，涵蓋肝細胞癌、肝內膽管癌和肝轉移性病變。臨床需求龐大，肝癌仍然是全球癌症死亡的主要原因之一，其預後很大程度上取決於早期發現、準確分期和治療選擇。診斷過程擴大結合血清生物標記（如胎兒球蛋白(AFP)）、肝功能檢查、病毒性肝炎檢測、超音波後續觀察、多期CT、造影MRI、切片檢查、組織病理學、免疫組織化學和分子譜分析。這種需求受到全球健康挑戰的影響，例如慢性B型肝炎、C型肝炎、酒精性肝病、代謝功能障礙相關的脂肪肝、糖尿病、肥胖、肝硬化和人口老化。最有效的診斷系統應將高風險患者的識別、定期後續觀察、及時的確診影像檢查、病理學能力和多學科決策聯繫起來。隨著醫療保健系統追求更早的診斷和更個人化的肝癌治療，市場條件越來越取決於精準診斷、簡化的工作流程、影像品質、生物標記檢驗和公平獲取。

肝癌診斷前景的變革性變化

肝癌診斷格局正受到三大變革的重塑：監測範圍擴大、精準腫瘤學的引入以及數位化工作流程的現代化。國際臨床指引建議對許多高風險肝硬化和慢性乙型肝炎患者群體進行半年一次的監測，這使得可靠的超音波檢查、標準化的影像學檢查以及基於生物標記的分流需求持續成長。同時，治療技術的進步也提升了腫瘤準確鑑別的重要性，包括區分肝細胞癌、膽管癌和轉移性疾病、評估血管侵犯以及在臨床適宜進行切片檢查或液態生物檢體時識別分子突變。放射學領域也在不斷發展，結構化報告、肝臟影像演算法、造影磁振造影方案和病灶鑑別工具都已改進。病理檢查室也在加強免疫組織化學和分子檢測能力，以支持診斷、預後和治療方案的發展。同時，在醫療資源分散且有限的地區，醫療機構也在發生變化，即時檢測、簡化的肝炎篩檢、遠距放射學和轉診網路正變得至關重要，以彌補診斷方面的不足。這些變革共同推動肝癌診斷從被動確認轉向主動、持續的風險管理。

人工智慧對肝癌診斷的累積影響

人工智慧正在對整個肝癌診斷流程產生累積影響，尤其是在影像學、風險預測、病理診斷和操作流程方面。在放射學領域，人工智慧驅動的工具正被開發用於輔助檢測局部肝髒病變、腫瘤分割、肝臟體積量化、放射組學分析，並提高CT、MRI和超音波影像解讀的一致性。在高風險族群中，結合年齡、性別、是否存在肝硬化、血小板計數、肝酵素水平、是否存在病毒性肝炎、糖尿病以及生物標記趨勢等臨床變數的機器學習模型，可以識別出哪些患者可能受益於加強監測並更快進入診斷階段。在病理學領域，經規範的臨床環境檢驗後，電腦輔助影像分析可以輔助進行模式識別、腫瘤分級和免疫組化定量分析。人工智慧在操作層面也發揮著至關重要的作用，例如優先處理可疑影像檢查、解決報告流程中的瓶頸問題以及支援多學科腫瘤學會議的籌備工作。然而，人工智慧的實施需要透明的檢驗、代表性的資料集、臨床醫生的監督、與醫院系統的互通性、網路安全以及監管合規性。人工智慧最有前景的影響並非取代臨床判斷，而是輔助專家決策，從而在診斷一致性、縮短診斷時間以及提高醫療服務的可及性方面取得可衡量的改進。

肝癌診斷的關鍵區域見解

亞太地區肝癌負擔特別沉重，這主要受慢性B型肝炎流行、部分地區黃麴毒素暴露、代謝性疾病日益增加以及人口基數大規模因素的影響。儘管中國、日本、韓國、印度、澳洲和東南亞國家在加強監測計畫、影像診斷能力、病毒性肝炎根除工作以及三級癌症轉診網路方面取得了進展，但農村地區的醫療服務可近性和成本效益仍存在差異。北美地區擁有先進的影像基礎設施、強大的病理學和分子檢測能力、多學科肝腫瘤會診的普及率高，以及對代謝功能障礙相關脂肪肝和肝硬化監測需求的不斷成長。拉丁美洲面臨著病毒性肝炎、酒精性肝病、肥胖等多種疾病帶來的複雜負擔，且專業影像和切片檢查服務的可及性存在差異，其中巴西和墨西哥是重要的診斷中心。歐洲已建立了完善的癌症治療路徑、肝炎控制措施、標準化的放射學以及健全的公共衛生監測系統，但由於人口老化和代謝性肝病的增加，診斷負擔仍在持續加重。在中東，對三級醫療、肝臟移植相關疾病計畫和先進影像技術的投資正在穩步推進，診斷需求主要受肝炎、代謝風險以及外籍人士健康需求的影響。在非洲，由於影像檢查資源有限、病理服務匱乏、就診延誤、部分地區乙型肝炎流行以及腫瘤轉診基礎設施不足等原因，醫療服務取得面臨最為嚴峻的挑戰。因此，普及可負擔的篩檢、肝炎疫苗接種以及診斷服務的去中心化至關重要。

肝癌診斷的關鍵區域見解

在東協地區，多個國家乙型肝炎負擔沉重，農村地區超音波和專科放射學資源匱乏，以及對癌症中心和肝炎預防計畫的投入增加，都對肝癌診斷產生了影響。海灣合作理事會（GCC）國家正透過高階醫院基礎設施、跨境專科醫療以及擴展影像和檢測能力來提升肝癌診斷能力，但代謝性疾病和病毒性肝炎病史仍然是監測需求的重要促進因素。歐盟正透過加強臨床指南、癌症登記、公共醫療保險報銷計畫、肝炎根除目標以及標準化影像和病理方案的使用，進一步促進診斷品質的統一。金磚國家（BRICS）的診斷情況則呈現出高度多樣性。中國和印度擁有龐大的高風險族群，巴西和俄羅斯面臨地理因素和系統能力差異，而南非則凸顯了加強肝炎診療、影像檢查、病理學和腫瘤治療之間協調的必要性。在七國集團（G7）國家，CT、MRI、病理學和分子檢測普遍普及，目前的重點是早期發現肝硬化、品質標準化以及整合人工智慧驅動的工作流程工具。北約成員國與歐洲和北美先進的醫療保健系統高度重合，在這些國家，診斷的可靠性、可互操作的數位醫療基礎設施以及獲得專業的腫瘤治療服務對於建立永續的肝癌診療體系至關重要。

各國肝癌診斷的關鍵見解。

美國擁有成熟的肝癌診斷體系，這得益於CT和MRI的廣泛普及、專業的肝病網路、病理學能力以及與肝硬化、丙型肝炎病史、酒精性肝病和代謝紊亂相關的脂肪肝等疾病日益成長的監測需求。在加拿大，基於指南的監測和地理分散人群的公平就醫至關重要，遠端醫療和集中式專科轉診發揮關鍵作用。在墨西哥和巴西，與肥胖、糖尿病、病毒性肝炎和酒精性肝病相關的診斷需求不斷成長，但都市區三級醫療機構和醫療資源匱乏地區之間高品質影像和病理學服務的可及性存在差異。在英國、德國、法國、義大利和西班牙，完善的公共衛生體系、肝病學專業知識、先進的影像技術以及透過癌症治療路徑進行的管治為肝癌診斷提供了支持，並日益重視早期診斷、放射學評估的標準化和基於生物標記的評估。在俄羅斯，主要城市擁有充足的診斷能力，但不同地區的就醫便利性和轉診效率存在差異。中國在全球肝癌診斷領域仍處於領先地位，這得益於其龐大的乙型肝炎相關高危險群、不斷完善的醫院基礎設施以及都市區先進影像和分子檢測技術的日益普及。在印度，由於肝炎、酒精性肝病和代謝風險等因素，肝癌診斷需求不斷成長，但醫療資源分配不均使得經濟實惠的監測和可擴展的影像檢查方案至關重要。日本和韓國在慢性病毒性肝炎管理、系統性監測、高品質影像檢查以及對早期肝細胞癌檢測的高度重視方面擁有豐富的經驗，因此備受推崇。澳洲則將先進的診斷基礎設施與全國性的癌症防治能力結合，同時也致力於滿足偏遠地區和原住民社區的醫療需求。

為行業領導者提供的實用建議

產業領導者應優先考慮經臨床檢驗的診斷解決方案，這些方案能夠提高早期檢測率、縮短診斷時間，並無縫整合到肝病學、放射學、病理學和腫瘤學的工作流程中。策略重點領域包括：提高監測環境中超音波的品質；在臨床適宜的情況下擴大造影磁振造影和多期CT的普及範圍；開發循證生物標記組合；支持相關病例的分子譜分析；以及構建在不同患者群體中展現出可重複臨床效用的AI工具。診斷服務提供者應投資於互通性、結構化報告、品質保證和安全的數據基礎設施，以支援對高風險患者的長期監測。與公共衛生計畫的合作可以加強乙型肝炎疫苗接種、丙型肝炎檢測和治療協調、肝硬化登記以及監測依從性。在新興市場，領導者應設計可擴展的模式，將經濟實惠的篩檢、轉診分診、遠距放射學、行動影像和人才培養相結合。在所有地區，最有吸引力的成長策略將是那些與循證臨床指南、監管標準、患者就醫途徑以及診斷準確性和護理協調方面的可衡量改進相一致的策略。

調查方法

本執行摘要基於系統性的二級研究途徑，利用了檢驗的臨床、監管、流行病學和公共衛生資訊來源。該調查方法重點關注國際癌症機構、同行評審的醫學文獻、肝病和腫瘤臨床指南、國家癌症控制資源、肝病監測出版物、衛生技術評估 (HTA) 結果以及公開的監管和報銷資訊。研究整合了各種診斷方法的見解，包括影像學、血清生物標記、組織病理學、免疫組織化學、分子診斷、液態生物檢體研究和人工智慧驅動的臨床決策支援。透過比較肝癌負擔、肝炎流行病學、肝硬化風險因素、影像基礎設施、實驗室能力、指南採納情況、醫療保健可近性以及數位化醫療應用觀點情況，建構了區域、群體和國家層面的視角。本分析不涉及市場規模、市場佔有率、收入估算和預測；而是著重於實證的臨床需求促進因素、技術採納模式、可近性障礙以及對相關人員的策略意義。

結論

肝癌診斷正邁入一個更加一體化的時代，早期檢測、風險分層、影像學準確性、病理學確診、分子水平洞察以及人工智慧驅動的工作流程最佳化等環節日益緊密地交織在一起。最大的機會在於提高高風險族群的篩檢依從性、縮短診斷延遲、擴大高品質影像學和病理學診斷的覆蓋範圍，以及在真實臨床實踐中驗證生物標記和數位化工具的檢驗。區域差異依然顯著，尤其是在肝炎高發生且專業診斷基礎設施有限的地區。同時，先進的醫療保健系統正在推進標準化報告、多學科診療以及精準腫瘤學的整合。將創新與臨床證據、監管要求、成本效益和醫療保健系統工作流程相結合的相關人員，將更有利於提高肝癌檢出率，並在全球範圍內改善患者的治療效果。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 肝癌診斷市場：依檢測類型分類

  • 生物標記
    • 遺傳標記
    • 蛋白質標記物
      • AFP偵測
      • DCP 測試
  • 切片檢查
    • 核心針穿刺切片
    • 細針穿刺切片檢查
  • 基因檢測
    • 次世代定序
    • PCR分析

第8章 肝癌診斷市場：依技術分類

  • 電腦斷層掃描
  • MRI
  • PET
  • 超音波

第9章 肝癌診斷市場：依癌症類型分類

  • 肝細胞癌
  • 膽管癌
  • 肝母細胞瘤

第10章 肝癌診斷市場：依最終用戶分類

  • 門診治療
  • 診斷中心
  • 醫院
  • 研究所

第11章 肝癌診斷市場：依疾病分期分類

  • 早期肝癌
  • 晚期肝癌

第12章 肝癌診斷市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 肝癌診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 肝癌診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Abbott Laboratories
  • AbbVie Inc.
  • Argon Medical Devices, Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Boston Scientific Corporation
  • Danaher Corporation
  • Epigenomics AG
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Hologic, Inc.
  • Illumina, Inc.
  • Intercept Pharmaceuticals, Inc. by Alfasigma SpA
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.
  • Vertex Pharmaceuticals Incorporated
Product Code: MRR-3A2E844FE71E

The Liver Cancer Diagnostics Market is projected to grow by USD 16.97 billion at a CAGR of 6.81% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 10.70 billion
Estimated Year [2026] USD 11.38 billion
Forecast Year [2032] USD 16.97 billion
CAGR (%) 6.81%

Liver cancer diagnostics is moving from episodic detection toward integrated, risk-based disease surveillance across hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and metastatic liver lesions. The clinical need is substantial: liver cancer remains among the leading causes of cancer mortality worldwide, and outcomes depend heavily on earlier detection, accurate staging, and treatment selection. Diagnostic pathways increasingly combine serum biomarkers such as alpha-fetoprotein, liver function assessment, viral hepatitis testing, ultrasound surveillance, multiphase CT, contrast-enhanced MRI, biopsy, histopathology, immunohistochemistry, and molecular profiling. Demand is shaped by the global burden of chronic hepatitis B, hepatitis C, alcohol-associated liver disease, metabolic dysfunction-associated steatotic liver disease, diabetes, obesity, cirrhosis, and aging populations. The most effective diagnostic ecosystems are those that connect high-risk patient identification, regular surveillance, timely confirmatory imaging, pathology capacity, and multidisciplinary decision-making. As health systems pursue earlier diagnosis and more personalized liver cancer care, the market landscape is increasingly defined by precision diagnostics, workflow efficiency, imaging quality, biomarker validation, and equitable access.

Transformative Shifts in the Liver Cancer Diagnostics Landscape

The liver cancer diagnostics landscape is being reshaped by three major shifts: surveillance expansion, precision oncology adoption, and digital workflow modernization. International clinical guidance supports semiannual surveillance for many high-risk cirrhosis and chronic hepatitis B populations, creating sustained demand for reliable ultrasound access, standardized imaging interpretation, and biomarker-supported triage. At the same time, therapeutic advances are increasing the importance of accurate tumor characterization, including differentiation of hepatocellular carcinoma from cholangiocarcinoma and metastatic disease, assessment of vascular invasion, and identification of molecular alterations where tissue or liquid biopsy is clinically appropriate. Radiology is also evolving through structured reporting, liver imaging algorithms, contrast-enhanced MRI protocols, and improved lesion characterization tools. Pathology laboratories are strengthening immunohistochemistry and molecular testing capabilities to support diagnosis, prognosis, and treatment planning. A parallel shift is occurring in decentralized and lower-resource settings, where point-of-care testing, simplified hepatitis screening, tele-radiology, and referral networks are becoming essential for closing diagnostic gaps. These transformations are collectively moving liver cancer diagnostics from reactive confirmation to proactive, continuous risk management.

Cumulative Impact of Artificial Intelligence on Liver Cancer Diagnostics

Artificial intelligence is becoming a cumulative force across the liver cancer diagnostic pathway, particularly in imaging, risk prediction, pathology, and operational workflow. In radiology, AI-supported tools are being developed to help detect focal liver lesions, segment tumors, quantify liver volume, support radiomics analysis, and improve consistency in CT, MRI, and ultrasound interpretation. In high-risk populations, machine learning models can incorporate clinical variables such as age, sex, cirrhosis status, platelet count, liver enzymes, viral hepatitis status, diabetes, and biomarker trends to identify patients who may benefit from intensified surveillance or faster diagnostic escalation. In pathology, computational image analysis can assist with pattern recognition, tumor grading support, and immunohistochemistry quantification when validated within regulated clinical environments. AI also has operational relevance by prioritizing suspicious imaging studies, reducing reporting bottlenecks, and supporting multidisciplinary tumor board preparation. However, adoption depends on transparent validation, representative datasets, clinician oversight, interoperability with hospital systems, cybersecurity, and regulatory compliance. The most credible AI impact will come from augmenting expert decision-making rather than replacing clinical judgment, with measurable gains in diagnostic consistency, turnaround time, and access.

Key Regional Insights Across Liver Cancer Diagnostics

Asia-Pacific carries a particularly high liver cancer burden, influenced by chronic hepatitis B prevalence, aflatoxin exposure in some settings, rising metabolic disease, and large population bases. China, Japan, South Korea, India, Australia, and Southeast Asian countries are strengthening surveillance programs, imaging capacity, viral hepatitis elimination initiatives, and tertiary oncology referral networks, although rural access and affordability remain uneven. North America is characterized by advanced imaging infrastructure, strong pathology and molecular testing capacity, high adoption of multidisciplinary liver tumor boards, and growing demand linked to metabolic dysfunction-associated steatotic liver disease and cirrhosis surveillance. Latin America faces a mixed burden from viral hepatitis, alcohol-related liver disease, obesity, and variable access to specialist imaging and biopsy services, with Brazil and Mexico serving as important diagnostic capacity centers. Europe benefits from established cancer pathways, hepatitis control efforts, radiology standardization, and strong public health surveillance, while demographic aging and metabolic liver disease continue to increase diagnostic pressure. The Middle East is investing in tertiary care, transplant-linked liver disease programs, and advanced imaging, with diagnostic demand shaped by hepatitis, metabolic risk, and expatriate population health needs. Africa faces the greatest access challenges due to limited imaging availability, pathology shortages, late presentation, hepatitis B endemicity in several regions, and constrained oncology referral infrastructure, making affordable screening, hepatitis vaccination, and diagnostic decentralization critical priorities.

Key Group Insights Across Liver Cancer Diagnostics

Within ASEAN, liver cancer diagnostics are influenced by a substantial hepatitis B burden in several countries, uneven rural access to ultrasound and specialist radiology, and growing investments in oncology centers and hepatitis prevention programs. GCC countries are advancing liver cancer diagnostic capabilities through high-end hospital infrastructure, cross-border specialist care, and expanding imaging and laboratory capacity, while metabolic disease and viral hepatitis history remain important drivers of surveillance demand. The European Union supports more harmonized diagnostic quality through clinical guidelines, cancer registries, public reimbursement systems, hepatitis elimination targets, and increasing use of structured imaging and pathology protocols. BRICS countries represent a highly diverse diagnostic environment: China and India account for large high-risk populations, Brazil and Russia face geographic and system-capacity disparities, and South Africa highlights the need for stronger linkage between hepatitis care, imaging access, pathology, and oncology treatment. G7 countries generally demonstrate strong availability of CT, MRI, pathology, and molecular testing, with current priorities centered on earlier detection in cirrhosis, quality standardization, and integration of AI-enabled workflow tools. NATO member countries overlap substantially with advanced European and North American health systems, where diagnostic resilience, interoperable digital health infrastructure, and access to specialized oncology services are increasingly important for sustained liver cancer care readiness.

Key Country Insights Across Liver Cancer Diagnostics

The United States has a mature liver cancer diagnostics ecosystem supported by broad CT and MRI availability, specialist hepatology networks, pathology capacity, and rising surveillance needs linked to cirrhosis, hepatitis C history, alcohol-associated liver disease, and metabolic dysfunction-associated steatotic liver disease. Canada emphasizes guideline-based surveillance and equitable access across geographically dispersed populations, with telehealth and centralized specialty referral playing important roles. Mexico and Brazil face growing diagnostic demand associated with obesity, diabetes, viral hepatitis, and alcohol-related liver disease, while access to high-quality imaging and pathology varies between urban tertiary centers and underserved regions. In the United Kingdom, Germany, France, Italy, and Spain, liver cancer diagnostics are supported by established public health systems, hepatology expertise, advanced imaging, and cancer pathway governance, with growing emphasis on earlier diagnosis, radiology standardization, and biomarker-informed assessment. Russia has significant diagnostic capacity in major cities but faces regional variation in access and referral efficiency. China remains central to global liver cancer diagnostics because of its large hepatitis B-associated risk population, expanding hospital infrastructure, and increasing use of advanced imaging and molecular testing in urban centers. India is experiencing rising demand from hepatitis, alcohol-related liver disease, and metabolic risk, while access disparities make affordable surveillance and scalable imaging pathways essential. Japan and South Korea are recognized for structured surveillance, strong imaging quality, and high clinical focus on early hepatocellular carcinoma detection, supported by extensive experience with chronic viral hepatitis management. Australia combines advanced diagnostic infrastructure with national cancer control capabilities, while also addressing access needs across remote and Indigenous communities.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated diagnostic solutions that improve early detection, shorten time to diagnosis, and integrate seamlessly into hepatology, radiology, pathology, and oncology workflows. Strategic focus areas include enhancing ultrasound quality in surveillance settings, expanding access to contrast-enhanced MRI and multiphase CT where clinically indicated, developing biomarker panels with robust evidence, supporting molecular profiling for appropriate cases, and building AI tools that demonstrate reproducible clinical utility across diverse patient populations. Diagnostic providers should invest in interoperability, structured reporting, quality assurance, and secure data infrastructure to support longitudinal monitoring of high-risk patients. Partnerships with public health programs can strengthen hepatitis B vaccination, hepatitis C testing and treatment linkage, cirrhosis registries, and surveillance adherence. In emerging markets, leaders should design scalable models that combine affordable screening, referral triage, tele-radiology, mobile imaging, and workforce training. Across all regions, the most defensible growth strategies will be those aligned with evidence-based clinical guidelines, regulatory standards, patient access, and measurable improvements in diagnostic accuracy and care coordination.

Research Methodology

This executive summary is based on a structured secondary research approach using verified clinical, regulatory, epidemiological, and public health sources. The methodology emphasizes evidence from international cancer agencies, peer-reviewed medical literature, hepatology and oncology clinical guidelines, national cancer control resources, liver disease surveillance publications, health technology assessment outputs, and publicly available regulatory and reimbursement information. Insights were synthesized across diagnostic modalities, including imaging, serum biomarkers, histopathology, immunohistochemistry, molecular diagnostics, liquid biopsy research, and AI-enabled clinical decision support. Regional, group, and country perspectives were developed by comparing liver cancer burden, hepatitis epidemiology, cirrhosis risk factors, imaging infrastructure, laboratory capacity, guideline adoption, healthcare access, and digital health readiness. The analysis excludes market sizing, market share, revenue estimation, and forecasting, focusing instead on evidence-backed clinical demand drivers, technology adoption patterns, access barriers, and strategic implications for stakeholders.

Conclusion

Liver cancer diagnostics is entering a more integrated era in which early detection, risk stratification, imaging precision, pathology confirmation, molecular insight, and AI-supported workflow efficiency are increasingly connected. The strongest opportunities lie in improving surveillance adherence among high-risk populations, reducing diagnostic delays, expanding access to high-quality imaging and pathology, and validating biomarkers and digital tools in real-world clinical settings. Regional disparities remain significant, particularly where hepatitis burden is high and specialist diagnostic infrastructure is limited. At the same time, advanced health systems are moving toward standardized reporting, multidisciplinary care, and precision oncology integration. Stakeholders that align innovation with clinical evidence, regulatory expectations, affordability, and health system workflows will be best positioned to improve liver cancer detection and support better patient outcomes worldwide.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Liver Cancer Diagnostics Market, by Test Type

  • 7.1. Introduction
  • 7.2. Biomarkers
    • 7.2.1. Genetic Markers
    • 7.2.2. Protein Markers
      • 7.2.2.1. AFP Tests
      • 7.2.2.2. DCP Tests
  • 7.3. Biopsy
    • 7.3.1. Core Needle Biopsy
    • 7.3.2. Fine Needle Aspiration
  • 7.4. Genetic Testing
    • 7.4.1. Next-Generation Sequencing
    • 7.4.2. PCR Analysis

8. Liver Cancer Diagnostics Market, by Technology

  • 8.1. Introduction
  • 8.2. CT Scan
  • 8.3. MRI
  • 8.4. PET
  • 8.5. Ultrasound

9. Liver Cancer Diagnostics Market, by Cancer Type

  • 9.1. Introduction
  • 9.2. Hepatocellular Carcinoma
  • 9.3. Cholangiocarcinoma
  • 9.4. Hepatoblastoma

10. Liver Cancer Diagnostics Market, by End User

  • 10.1. Introduction
  • 10.2. Ambulatory Care
  • 10.3. Diagnostic Centers
  • 10.4. Hospitals
  • 10.5. Research Laboratories

11. Liver Cancer Diagnostics Market, by Disease Stage

  • 11.1. Introduction
  • 11.2. Early-Stage Liver Cancer
  • 11.3. Advanced-Stage Liver Cancer

12. Liver Cancer Diagnostics Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Liver Cancer Diagnostics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Liver Cancer Diagnostics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Abbott Laboratories
  • 16.2. AbbVie Inc.
  • 16.3. Argon Medical Devices, Inc.
  • 16.4. AstraZeneca PLC
  • 16.5. Bayer AG
  • 16.6. Becton, Dickinson and Company
  • 16.7. Bio-Rad Laboratories, Inc.
  • 16.8. bioMerieux SA
  • 16.9. Boston Scientific Corporation
  • 16.10. Danaher Corporation
  • 16.11. Epigenomics AG
  • 16.12. F. Hoffmann-La Roche Ltd.
  • 16.13. Gilead Sciences, Inc.
  • 16.14. GlaxoSmithKline plc
  • 16.15. Hologic, Inc.
  • 16.16. Illumina, Inc.
  • 16.17. Intercept Pharmaceuticals, Inc. by Alfasigma S.p.A.
  • 16.18. Merck & Co., Inc.
  • 16.19. Novartis AG
  • 16.20. Pfizer, Inc.
  • 16.21. Siemens Healthineers AG
  • 16.22. Sysmex Corporation
  • 16.23. Takeda Pharmaceutical Company Limited
  • 16.24. Thermo Fisher Scientific Inc.
  • 16.25. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. GLOBAL LIVER CANCER DIAGNOSTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL LIVER CANCER DIAGNOSTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL LIVER CANCER DIAGNOSTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL LIVER CANCER DIAGNOSTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL LIVER CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENETIC MARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GENETIC MARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENETIC MARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PROTEIN MARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PROTEIN MARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PROTEIN MARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL AFP TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL AFP TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL AFP TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DCP TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DCP TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DCP TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CORE NEEDLE BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CORE NEEDLE BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CORE NEEDLE BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL FINE NEEDLE ASPIRATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL FINE NEEDLE ASPIRATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL FINE NEEDLE ASPIRATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GENETIC TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENETIC TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PCR ANALYSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PCR ANALYSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PCR ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CT SCAN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CT SCAN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CT SCAN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MRI MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MRI MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MRI MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PET MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PET MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ULTRASOUND MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ULTRASOUND MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ULTRASOUND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HEPATOCELLULAR CARCINOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HEPATOCELLULAR CARCINOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CHOLANGIOCARCINOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CHOLANGIOCARCINOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CHOLANGIOCARCINOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HEPATOBLASTOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HEPATOBLASTOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HEPATOBLASTOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL AMBULATORY CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL AMBULATORY CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL AMBULATORY CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DIAGNOSTIC CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DIAGNOSTIC CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DIAGNOSTIC CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL EARLY-STAGE LIVER CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL EARLY-STAGE LIVER CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL EARLY-STAGE LIVER CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ADVANCED-STAGE LIVER CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ADVANCED-STAGE LIVER CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ADVANCED-STAGE LIVER CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 152. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 155. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 156. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 157. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 158. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 159. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 182. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 185. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 186. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 187. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 188. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 189. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 192. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 193. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 195. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 196. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 197. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 198. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 213. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 214. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 216. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 217. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 218. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 219. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 220. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 223. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 226. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 227. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 228. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 229. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 230. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 233. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 236. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 237. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 238. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 239. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 240. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 253. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 256. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 257. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 258. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 259. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 260. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 263. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 264. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 266. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 267. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 268. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 269. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 270. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 273. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 274. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 276. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 277. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 278. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 279. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 280. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 282. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 283. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 284. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 286. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 287. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 288. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 289. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 290. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 292. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 293. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 294. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 296. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 297. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 298. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 299. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 300. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 302. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 305. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 306. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 307. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 310. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 312. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 313. INDIA LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 314. INDIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 315. INDIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 316. INDIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 317. INDIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 318. INDIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 319. INDIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 320. INDIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 321. INDIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 322. INDIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 323. JAPAN LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 324. JAPAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 325. JAPAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 326. JAPAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 327. JAPAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 328. JAPAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 329. JAPAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 330. JAPAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 331. JAPAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 332. JAPAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 333. AUSTRALIA LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 334. AUSTRALIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 335. AUSTRALIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 336. AUSTRALIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 337. AUSTRALIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 338. AUSTRALIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 339. AUSTRALIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 340. AUSTRALIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 341. AUSTRALIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 342. AUSTRALIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 343. SOUTH KOREA LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 344. SOUTH KOREA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 345. SOUTH KOREA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 346. SOUTH KOREA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 347. SOUTH KOREA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 348. SOUTH KOREA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 349. SOUTH KOREA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 350. SOUTH KOREA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 351. SOUTH KOREA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 352. SOUTH KOREA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 353. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 354. GLOBAL LIVER CANCER DIAGNOSTICS MARKET